Amongpatients with HER2-negative cancer receiving first-line CapOx/FOLFOX, median OSwas 7.8, 7.8, and 7.7 months for EAC, GEJC, and GAC, respectively(p = 0.89; Figure 4(b)). The gene discussed is ERBB2; the disease is cancer.